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Abstract Strontium ranelate (SR) is an orally
administered and bone-targeting anti-osteoporotic
agent that increases osteoblast-mediated bone forma-
tion while decreasing osteoclastic bone resorption, and
thus reduces the risk of vertebral and femoral bone
fractures in postmenopausal women with osteoporo-
sis. Osteoblastic alkaline phosphatase (ALP) is a key
enzyme involved in the process of bone formation and
osteoid mineralization. In this study we investigated
the direct effect of strontium (SR and SrCl2) on the
activity of ALP obtained from UMR106 osteosarcoma
cells, as well as its possible interactions with the
divalent cations Zn2? and Mg2?. In the presence of
Mg2?, both SR and SrCl2 (0.05–0.5 mM) significantly
increased ALP activity (15–66 % above basal), and
this was dose-dependent in the case of SR. The
stimulatory effect of strontium disappeared in the
absence of Mg2?. The cofactor Zn2? also increased
ALP activity (an effect that reached a plateau at
2 mM), and co-incubation of 2 mM Zn2? with
0.05–0.5 mM SR showed an additive effect on ALP
activity stimulation. SR induced a dose-dependent
decrease in the Km of ALP (and thus an increase in
affinity for its substrate) with a maximal effect at
0.1 mM. Co-incubation with 2 mM Zn2? further
decreased Km in all cases. These direct effects of SR
on osteoblastic ALP activity could be indicating an
alternative mechanism by which this compound may
regulate bone matrix mineralization.
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Introduction
Strontium ranelate (SR) is an orally administered anti-
osteoporotic agent that includes two strontium ions
and an organic moiety (ranelic acid) Saidak and Marie
(2012) Sr2? can partially substitute Ca2? in hydroxy-
apatite, and thus be incorporated into bone. SR has
been shown to effectively reduce the risk of vertebral
and femoral bone fractures in postmenopausal women
with osteoporosis (Meunier et al. 2004; Reginster et al.
2005). In vitro, strontium exerts a dual effect on bone
cells: it increases osteoblast-mediated bone formation,
while decreasing osteoclastic bone resorption (Saidak
and Marie 2012; Takaoka et al. 2010).These combined
actions correlate with its beneficial effects on bone
mass, bone quality and bone resistance in animal
models of metabolic bone disease, as well as in
osteoporotic patients. In osteoblasts, strontium stim-
ulates cellular proliferation and differentiation via the
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calcium sensing receptor and the Wnt/beta-catenin
pathway (Takaoka et al. 2010).
Mature osteoblasts express high levels of tissue
specific alkaline phosphatase (ALP), a key enzyme
involved in the process of bone formation and
osteoid mineralization (Whyte 1994). This marker
of osteoblastic differentiation is a metallo-enzyme
anchored to both the plasma membrane and to
secreted matrix vesicles (Van Hoof and De Broe
1994). ALP is a phosphomonoesterase, whose
catalytic activity depends on a multimeric config-
uration. It requires Mg2? as a cofactor and includes
two Zn2? ions per monomer to stabilize its tertiary
structure. Because ALP is an exoenzyme that faces
the extracellular compartment, it is conceivable to
hypothesize that its activity and function could be
modulated by environmental conditions and phar-
macological treatments. For instance, we have
previously provided evidence for the alteration of
ALP activity and structure as a consequence of its
in vitro glycation (McCarthy et al. 1998) and of its
co-incubation with N-containing bisphosphonates
(Vaisman et al. 2005).
Sr2?, when orally administered as SR, is partially
incorporated into bone (Dahl et al. 2001). After a
treatment of 4 weeks or more, plasma levels and bone
content of strontium reach a plateau, with a very good
correlation between them both. However, strontium
content of bone can additionally vary according to its
turnover and anatomical localization: for example,
higher amounts of strontium are found in cancellous
bone than in cortical bone.
In recent in vitro studies with MC3T3E1 osteo-
blastic cells, we have shown that Sr2? can increase
type 1 collagen production, ALP specific activity and
expression of intracellular markers such as extracel-
lular-regulated kinases (ERK) and b-catenin, while
decreasing secretion of the pro-inflammatory cyto-
kines TNFa and IL1 (Fernandez et al. 2013). Sr2?
incorporated into the mineral lattice could directly
interact with bone-ALP expressed by osteoblasts and/
or present in secreted matrix vesicles, thus potentially
influencing the process of osteoid mineralization. In
the present study, we have investigated the direct
effect of strontium (as ranelate and chloride) on the
activity of osteoblast-derived ALP, as well as possible
mechanisms that involve its interaction with the
divalent cations Zn2? and Mg2?.
Materials and methods
Materials
SR was provided by Servier, Argentina. Dulbecco’s
modified Eagle’s medium (DMEM), trypsin–EDTA,
and fetal bovine serum (FBS) were from Gibco, (Life
Technology, Buenos Aires, Argentina) and tissue
culture disposable material was from Nunc (Buenos
Aires, Argentina). Para-nitrophenyl phosphate (p-NPP),
strontium chloride, wheat germ agglutinin (WGA) and
other reagents of analytical grade were obtained from
Sigma Chemical Co. (St. Louis, MO, USA).
Cell culture
UMR106 rat osteosarcoma-derived cells were
obtained from American Type Culture Collection
(ATCC) (Rockville, MI, USA). Cells were grown in
75-cm2 flasks at 37 C in a humidified 5 % CO2
atmosphere in DMEM supplemented with 100 U/mL
penicillin, 100 lg/mL streptomycin and 10 % FBS.
When 70–80 % confluence was reached, cells were
sub-cultured using 0.1 % trypsin–1 mM EDTA in
Ca?2–Mg?2-free phosphate-buffered saline (PBS).
After cells reached confluence, the monolayer was
washed with PBS and solubilised in 0.1 % Triton
X-100. After that, osteoblastic ALP was purified by its
affinity for WGA. Briefly, a volume of total cell
extract was incubated for 30 min with the same
volume of WGA (5 mg/ml) (Broyles et al. 1998;
Farley et al. 1994; Puche et al. 1988), after which the
precipitate was separated by centrifugation and resus-
pended in an equal volume of PBS. Aliquots of ALP
thus purified were used for evaluation of enzymatic
activity as described below. We have previously
characterized ALP from UMR106 cell extracts (Va-
isman et al. 2005).
Alkaline phosphatase activity assay
The initial rate of ALP enzymatic activity from WGA-
isolates was determined by spectrophotometric eval-
uation of hydrolysis of p-NPP to p-nitrophenol (p-NP)
in a glycine–Mg buffer, pH 10.5, at 37 C for 5 min.
Alternatively, a glycine buffer without Mg was used.
Formation of the product was assessed by absorbance
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at 405 nm with a PG Instruments T60 UV–visible
spectrophotometer. Under these conditions, the reac-
tion proceeds linearly for 30 min. The effects of
different doses of SR, SrCl2 and/or ZnCl2 were tested
after their pre-incubation for 10 min at 37 C with
identical aliquots of the same osteoblastic extract.
Results are expressed as the initial rate of bone-
specific ALP activity (nmol pNP/min).
To determine if SR affects the affinity (Km) for
p-NPP, we evaluated the production of p-NP after 2
and 5 min of reaction with an aliquot of the extract and
increasing concentrations of SR, with or without Zn?2,
in a glycine—Mg buffer. The Km was calculated








Where V is the reaction velocity, Km is the
Michaelis–Menten constant, Vmax is the maximum
reaction velocity and [S] is concentration of substrate.
Statistical analysis
For each experimental condition, at least three sepa-
rate experiments were performed by triplicate. Data
are expressed as the mean ± SEM. Statistical differ-
ences were analyzed using Student’s t test, and a
p \ 0.05 was considered to be significant.
Results
We have previously characterized ALP from UMR106
cell extracts by heat inactivation, showing that this
bone isoform represents about 90 % of total cellular
ALP (Vaisman et al. 2005). Among other character-
istics, ALP iso-enzymes differ in their post-transla-
tional glycosylation and thus in their affinity for
specific lectins. In particular, bone-ALP shows high
affinity for WGA, and thus can be easily separated
from other iso-enzymes by selective precipitation with
this lectin (Farley et al. 1994). In the present study we
investigated the possible modulation of the activity of
WGA-precipitated ALP by SR and SrCl2. Under our
experimental conditions, SR significantly stimulated
the initial rate of p-NPP hydrolysis in a dose-depen-
dent manner (Fig 1a; Table 1) as from 0.05 mM of
SR. The maximal effect at the evaluated doses was
observed for 0.5 mM of SR (66 % over basal). ALP
activity was also increased about 30 % over basal by
0.01–0.1 mM SrCl2, although in this concentration
range the effect of SrCl2 did not appear to be dose-
dependent (Fig 1b; Table 1).
Since bone-specific ALP requires Mg2? as a
cofactor, we investigated whether Sr2? could be
replacing this ion to stimulate ALP activity. To
address this question, we examined the possible effect
of different doses of SR on bone-specific ALP activity
in the absence of Mg2? in the incubation buffer. As
can be seen in Fig 1c and Table 1, Mg2?-deprivation
significantly inhibited ALP activity by about 30 %,
and this inhibition could not be overcome by co-
incubation with 0.01–0.5 mM SR. In fact, 0.5 mM SR
actually tended to inhibit (by about 50 %) the
remaining bone-specific ALP activity, although this
did not reach statistical significance.
We next examined the effect on bone-specific ALP
activity of increasing cofactor (Zn2?) concentration.
As can be seen in Fig 2a, b, Zn2? increased ALP
activity in a dose-dependent manner, with a maximal
stimulation reached at 2 mM ZnCl2 (220 % of basal,
p \ 0.001).
Results presented in Figs 1 and 2 show that in our
experimental conditions both Sr2? and Zn2? stimulate
bone-specific ALP activity. Hence, we sought to
determine if there might be synergistic or additive
interactions between both ions. In further experiments
we evaluated the effect on ALP activity of 2 mM Zn2?
plus two doses (0.05 or 0.5 mM) of SR. The results are
shown in Fig 3. In the presence of Zn2?, 0.05 mM SR
stimulated ALP activity (267 % of basal, p \ 0.001),
and this effect was significantly greater than the effects
of 2 mM Zn2? alone (p \ 0.05) or of 0.05 mM SR
alone (p \ 0.001). Likewise in the presence of Zn2?,
0.5 mM SR significantly increased bone-ALP activity
over control (306 % versus basal, p \ 0.001) as well
as over 2 mM Zn2? alone (p \ 0.001). Our results
suggest an additive effect for both divalent cations
(Sr2? and Zn2?) on bone-ALP activity.
In order to characterize the effect of SR on the
kinetic parameters of ALP, the WGA-isolates were
incubated with different concentrations of SR (0, 0.05,
0.1 and 0.5 mM) in the absence or presence of 2 mM
Zn2?. The initial rates were determined with increas-
ing concentrations of pNPP and the values were
plotted as Michaelis–Menten curves in Fig. 4. Our
results show that SR on its own dose-dependently
increased ALP reaction velocity. In addition, co-
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incubation with Zn2? potentiated the effect of SR on
ALP initial rate. Using the equation of Lineweaver–
Burk we determined Km for each experimental
condition (Fig. 5). As can be seen, SR induced a
dose-dependent decrease in Km (and thus an increase
in the affinity of ALP for its substrate) with a maximal
effect at 0.1 mM. Co-incubation with 2 mM Zn2?
further decreased Km in all cases.
Fig. 1 Direct effect of strontium on alkaline phosphatase
activity. a SR stimulates ALP activity in a dose-dependent
manner, while b SrCl2 stimulates ALP activity similarly at all
doses tested. c Mg2?-deprivation inhibited ALP activity and this
inhibition could not be overcome by co-incubation with
0.01–0.5 mM SR
Table 1 Initial rate of ALP activity (nmol pNP/min)
Sr2? (mM) SR SrCl2 SR w/o Mg
0 0.95 ± 0.01 0.95 ± 0.01 0.68 ± 0.09*
0.01 0.98 ± 0.033 1.23 ± 0.08* 0.66 ± 0.12*
0.05 1.07 ± 0.03* 1.21 ± 0.13 0.65 ± 0.18*
0.1 1.31 ± 0.10* 1.24 ± 0.08* 0.68 ± 0.08*
0.5 1.58 ± 0.14** 1.04 ± 0.12 0.38 ± 0.13**
Difference versus Basal (without Sr2?, with Mg2?):
* p \ 0.05, ** p \ 0.02
Fig. 2 Zinc is a cofactor for ALP activity. Zn?2 increases ALP
activity in a time (a) and dose (b) dependent manner
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Discussion
Recent reports have demonstrated that the beneficial
effects of SR on bone metabolism result from differ-
ential effects of this agent on the recruitment and
activity of both osteoclasts and osteoblasts. SR
increases the replication of pre-osteoblastic cells as
well as the activity of functional osteoblasts, resulting
in increased bone matrix synthesis (Saidak and Marie
2012). On the other hand, SR inhibits osteoclast
formation by antagonizing RANKL-induced nuclear
translocation of NF-jB and AP-1 transcription factors
(Caudrillier et al. 2010). Although many effects of SR
are probably mediated by interaction of Sr2? with the
calcium-sensing receptor and activation of pathways
such as ERK and Wnt/b-catenin (Takaoka et al. 2010),
recently Yamaguchi and Weitzmann (2012) have
suggested that certain biological actions of SR could
be related to low doses of the intact (undissociated)
molecule. However, no studies have reported the
direct effect of Sr2? (and specifically SR) on osteo-
blast-derived phosphatases. In the present study we
sought to investigate the possible direct effect of SR on
bone-specific ALP activity, as an alternative mecha-
nism by which this compound could regulate matrix
mineralization.
We have shown that Sr2? exerts a direct stimulation
of osteoblast-derived and WGA-precipitated ALP
activity. At the concentrations evaluated, this effect
was dose-dependent when the agent tested was SR but
not with SrCl2. The differences observed between both
compounds at low concentrations could be due to
differing levels of free Sr2? as a consequence of a
lower dissociation of SR. In fact, ALP activity with
0.01 mM SR (Table 1) was similar to that with
0.001 mM SrCl2 (data not shown), which is in
agreement with an incomplete dissociation of SR.
The concentrations of strontium tested in this study
were chosen based on our (and other) previous studies
on its in vitro effects on osteoblasts in culture
(Yamaguchi and Weitzmann 2012; Fernandez et al.
2010; Fernandez et al. 2013; Barbara et al. 2004). In
addition, the strontium serum concentration in post-
Fig. 3 Strontium ranelate and zinc have an additive effect on
ALP activity. Different doses of SR and 2 mM Zn?2 stimulate
ALP activity. The combination of both drugs results in an
additive increase in ALP activity
Fig. 4 Effects of Zn2? and SR on kinetics of ALP-catalyzed
hydrolysis of pNPP. The initial rates of hydrolysis of increasing
concentrations of pNPP in the presence of 0 mM Zn2? (white
symbols) or 2 mM Zn2? (black symbols) and different concen-
trations of SR were determined
Fig. 5 Representation of the Michaelis–Menten constant (Km)
of ALP for different concentrations of SR and/or Zn2?
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menopausal women with osteoporosis in long-term
treatment with SR has been reported to be in the range
of 0.1–0.2 mM (Marie 2008) Our previous results
(Fernandez et al. 2013) and those of other authors
show that levels of SR around 0.1 mM are optimal for
increasing osteoblast activity and function. This
coincides with our present results showing that
0.1 mM of SR lowers the Km of ALP, thus increasing
affinity of the enzyme for its experimental substrate
(Fig. 5a, b). Under normal calcium dietary intake,
strontium incorporation into the bone matrix corre-
lates with serum strontium levels. Using a synchrotron
radiation-induced micro X-ray fluorescence (SR
m-XRF) method, concentrations of strontium were
determined in bone tissue (Roschger et al. 2010; Fuchs
et al. 2008). However, the strontium levels reported by
this technique were expressed in relative values
(wt %), and thus it is not possible to compare with
the in vitro or in vivo serum levels of strontium, as has
recently been emphasised by Roschger and coworkers
(2011). Nevertheless, it is possible that strontium
accumulated in the bone matrix could directly regulate
osteoblast-derived ALP during the mineralization
process, as our present observations suggest.
It is known that tissue non-specific ALPs are
strongly regulated by Mg2? and Zn2? (Bosron et al.
1977). Our present results suggest that Mg2? cannot be
replaced by SR. Indeed, in our experimental condi-
tions strontium-induced ALP activation required the
presence of Mg2? in the incubation media. In agree-
ment with our results, previous investigations have
proposed that Mg2? is necessary for ALP activity
because it maintains the tertiary structure of the
enzyme (Anderson et al. 1975). On the other hand; we
found an additive effect of SR and Zn2? on ALP
stimulation. In concordance with our observations,
other authors (Llinas et al. 2006) have proposed the
presence of a four-metal binding site in ALP. Based on
crystallographic and sequence homology studies
between the non-specific (present in bone) and
placental ALP isoforms they proposed that this
binding site should be occupied by calcium, which
can be substituted by strontium. Other authors have
also suggested that strontium could act as a competitor
for binding site(s) in proteins such as ALP that are
specific to cellular function (Fielding Fielding et al.
2012). Altogether, our present and previous observa-
tions suggest that strontium induces activation of ALP
through its affinity for a specific metal-binding site,
thus potentially regulating its activity during osteoid
mineralization.
In conclusion, this study has demonstrated for the
first time a direct stimulation of bone-derived ALP
activity by strontium (and particularly by SR) that is
partly due to a SR-induced increase in the affinity of
this enzyme for its substrate.
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